NDAORALTABLET
Approved
Apr 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 49m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERCODAN is an oral tablet combining aspirin and oxycodone hydrochloride, a Schedule II opioid analgesic indicated for moderate to moderately severe pain. It is a classic fixed-dose combination product approved in 1950 that works through oxycodone's mu-opioid receptor agonism combined with aspirin's analgesic and anti-inflammatory effects.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), expect minimal team expansion and focus on defensive retention strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PERCODAN offers limited career growth as it is a legacy product in LOE approach with minimal linked job openings. Roles focus on maximizing remaining revenue and managing market transition rather than driving innovation or market expansion.
Brand ManagerCommercial Analyst
Worked on PERCODAN at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.